Your browser doesn't support javascript.
loading
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo.
Howell, Imran; Bratton, Daniel J; Hynes, Gareth; Yancey, Steven W; Heaney, Liam G; Pavord, Ian D; Shrimanker, Rahul.
Affiliation
  • Howell I; Oxford Respiratory NIHR BRC and Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bratton DJ; Clinical Statistics, GSK, Brentford, UK.
  • Hynes G; Oxford Respiratory NIHR BRC and Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Yancey SW; Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.
  • Heaney LG; Department of Respiratory Medicine, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
  • Pavord ID; Oxford Respiratory NIHR BRC and Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Shrimanker R; Bristol Academic Respiratory Unit, Bristol, UK.
ERJ Open Res ; 10(4)2024 Jul.
Article in En | MEDLINE | ID: mdl-39076523
ABSTRACT
Asthma exacerbations in people treated with mepolizumab result in less peak expiratory flow reduction than placebo but similar symptom scores. Symptoms recover slower, indicating these exacerbations may be less prednisolone responsive. https//bit.ly/3xQsFRB.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Journal: ERJ Open Res Year: 2024 Type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Language: En Journal: ERJ Open Res Year: 2024 Type: Article Affiliation country: United kingdom